Citations

Clear

1906 citation(s) found for "Yu, Frank".

Survival trends in palliative care patients with cancer: A Mayo Clinic 5-year review
Liu, H., Ruegg, S. R., Carey, Elise C. , Whitford, Kevin J. , Bock, Frank Andrew, Creagan, Edward T. , Moynihan, T. J., Kaur, Judith S. , Kamal, Arif H. , Swetz, Keith M.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 9592-9592

10.1200/jco.2009.27.15_suppl.9592 Get It

9592 Background: Palliative care (PC) is an essential part of the continuum of care for cancer (CA) patients (pts). Little is known about the aggregate characteristics and survival of pts receiving inpatient palliative care consultation (PCC). Methods: We reviewed data prospectively collected on patients seen by the Palliative Care Inpatient Consult Service at Mayo Clinic - Rochester from 2003–2008. Demographics, consult characteristics, and survival were analyzed. Kaplan-Meier survival curves and a Cox model of survival were produced. Results: 1794 total patients were seen over the five year period. Cancer is the most common primary diagnosis (47%). Growth in annual PCC has risen dramatically (113 in 2003 vs. 414 in 2007) despite stable total hospital admissions. Patient are predominantly men (52% vs. 48%, p=0.02); median age is 76. General medicine, medical cardiology, and medical intensive care unit services refer most often. Most frequent issues addressed are goals of care, dismissal planning, and pain control (29%, 19%, 17%). PCC in actively dying pts have increased with 27% of all non-operating room, non-trauma in-hospital deaths being seen. Although CA pts have the highest median survival after PCC vs. other diagnoses (17 days, p = 0.018), we observed a five-year trend of decreasing survival from admission to death and PCC to death. Median time from admission to death in CA pts is 36 days in 2003 and 19 days in 2008 (p<0.01). Median time from PCC to death is 33 versus 11.5 days (p<0.01). Despite this, median hospital length of stay and time from PCC to discharge have remained fixed at 8 and 2.5 days, respectively. A Cox model of survival to discharge and <6 months survival (hospice eligibility) shows hospital length of stay, time from consult to discharge, and dismissal location from hospital are all prognostic factors. Conclusions: Survival window for PC intervention for CA pts is lessening. With the trend of shorter survival after PCC, PC professionals have little over two days to implement a comprehensive, ongoing care plan. This highlights the importance of earlier outpatient palliative care involvement with advanced cancer patients and families. No significant financial relationships to disclose.
Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy
Granberg, Candace F. , Thompson, R. Houston, Quevedo, J. Fernando , Karnes, R. Jeffrey , Frank, Igor, Blute, Michael L., Kwon, E.D.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: e16103-e16103

10.1200/jco.2009.27.15_suppl.e16103 Get It

e16103 Background: At present, androgen ablation (AA) therapy ± radiation therapy represents a first-line treatment for patients with unresectable locally advanced prostate cancer (CAP), typically resulting in palliative disease control. Immunotherapy, in the form of CTLA-4 blockade, has been shown to potentiate T-cell responses, representing a potential antitumoral immunotherapy for treating CAP. Here, we discuss the outcomes of 5 locally advanced CAP patients treated with the monoclonal antibody MDX-CTLA-4 (MDX-010) + AA who subsequently underwent radical prostatectomy (RP), 2 of whom exhibited striking down-staging of their disease. Methods: A Phase II trial testing AA + MDX-010 therapy for treatment of locally or systemically advanced CAP is currently ongoing at our institution. To date, 5/85 patients have electively opted for off-study RP with extended pelvic lymphadenectomy after documentation of robust treatment response by PSA, staging digital rectal exam, and 3-D imaging. Results: All men had unresectable, locally advanced disease (stage T2c-T4) prior to treatment with AA + MDX-010 and subsequently underwent RP. Median blood loss was 400mL (400–900). All patients had negative surgical margins. Of the 5 patients, 2 exhibited dramatic and indisputable down-staging of their disease. These two patients presented with 80% of biopsies involved with cancer, extraprostatic extension, seminal vesicle (SV) invasion, and bladder base involvement. On final pathology, both exhibited extensive treatment effect, remission of SV involvement, and robust disaggregation of solid tumors resulting in only microscopic, non-contiguous foci of residual intraprostatic cancer. Both had T4 disease pre-treatment, and had stage T2c on final pathology. One patient is free of disease with undetectable PSA for 19 months following adjuvant radiation treatment but no further therapy, while the other patient is awaiting follow-up. Conclusions: We have been able to demonstrate true down-staging of locally advanced prostate cancer with neoadjuvant AA + MDX-010 therapy. This therapeutic modality exhibits significant promise for men with unresectable disease and may provide durable and potentially curative cancer control. No significant financial relationships to disclose.
Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction
Horiuchi, Yu , Wettersten, Nicholas , Patel, Mitul , Mueller, Christian, Neath, Sean‐Xavier , Christenson, Robert H. , Morgenthaler, Nils G., McCord, James , Nowak, Richard M. , Vilke, Gary M. , Daniels, Lori B. , Apple, Fred S. , Cannon, Chad , Nagurney, John Tobias , Schreiber, Donald , Diercks, Deborah B. , Headden, Gary , Limkakeng, Alexander T. , Wu, Alan H.B. , Ebmeyer, Stefan , Jaffe, Allan S. , Peacock, W. Frank, Maisel, Alan , Müller, Christian , Mueller, Christian , Daniels, Lori B , Hollander, Judd E. , deFilippi, Christopher R. , Hogan, Christopher J. , Anand, Inder S. , Jaffe, Allan S.

Mayo Clinic

Circulation | August 21, 2020 | Volume: 142 | Issue: 16 | Pages: 1532-1544

10.1161/circulationaha.120.046682 | PMID 32820656 Get It

Background: The observed incidence of type 2 myocardial infarction (T2MI) is expected to increase with the implementation of increasingly sensitive cTn assays. However, it remains to be determined how to diagnose, risk-stratify, and treat patients with T2MI. We aimed to discriminate and risk-stratify T2MI using biomarkers. Methods: Patients presenting to the emergency department with chest pain, enrolled in the CHOPIN study (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction), were retrospectively analyzed. Two cardiologists adjudicated type 1 MI (T1MI) and T2MI. The prognostic ability of several biomarkers alone or in combination to discriminate T2MI from T1MI was investigated using receiver operating characteristic curve analysis. The biomarkers analyzed were cTnI, copeptin, MR-proANP (midregional proatrial natriuretic peptide), CT-proET1 (C-terminal proendothelin-1), MR-proADM (midregional proadrenomedullin), and procalcitonin. The prognostic utility of these biomarkers for all-cause mortality and major adverse cardiovascular event (a composite of acute myocardial infarction, unstable angina pectoris, reinfarction, heart failure, and stroke) at 180-day follow-up was also investigated. Results: Among the 2071 patients, T1MI and T2MI were adjudicated in 94 and 176 patients, respectively. Patients with T1MI had higher levels of baseline cTnI, whereas those with T2MI had higher baseline levels of MR-proANP, CT-proET1, MR-proADM, and procalcitonin. The area under the receiver operating characteristic curve for the diagnosis of T2MI was higher for CT-proET1, MR-proADM, and MR-proANP (0.765, 0.750, and 0.733, respectively) than for cTnI (0.631). Combining all biomarkers resulted in a similar accuracy to a model using clinical variables and cTnI (0.854 versus 0.884, P =0.294). Addition of biomarkers to the clinical model yielded the highest area under the receiver operating characteristic curve (0.917). Other biomarkers, but not cTnI, were associated with mortality and major adverse cardiovascular event at 180 days among all patients, with no interaction between the diagnosis of T1MI or T2MI. Conclusions: Assessment of biomarkers reflecting pathophysiologic processes occurring with T2MI might help differentiate it from T1MI. All biomarkers measured, except cTnI, were significant predictors of prognosis, regardless of the type of myocardial infarction.
Polymyalgia Rheumatica and Giant Cell Arteritis
Buttgereit, Frank , Matteson, Eric L. , Dejaco, Christian , Dejaco, Christian , Buttgereit, Frank

Mayo Clinic

JAMA | August 19, 2020 | Volume: 324 | Issue: 10 | Pages: 993

10.1001/jama.2020.10155 | PMID 32897333 Get It

Hospital discharge hemoglobin values and posthospitalization clinical outcomes in transfused patients undergoing noncardiac surgery
Kerfeld, Mitchell J. , Kor, Daryl J. , Frank, Ryan D. , Hanson, Andrew C. , Passe, Melissa, Warner, Matthew A. , Passe, Melissa A, Warner, Matthew A

Mayo Clinic

Transfusion | August 14, 2020 | Volume: 60 | Issue: 10 | Pages: 2250-2259

10.1111/trf.16002 | PMID 32794229 Get It

AbstractBackgroundRed blood cell (RBC) transfusion is common in surgical patients, yet optimal transfusion targets are incompletely defined in the perioperative period. Hemoglobin levels at the time of hospital discharge may provide insight into transfusion practices, anemia management, and patient outcomes.Study Design and MethodsThis is an observational cohort study of adults receiving RBC transfusion during noncardiac surgery from 2010 to 2014. Multivariable regression was used to assess the relationships between hospital discharge hemoglobin concentrations, anemia severity (severe: <8 g/dL; moderate: 8‐10 g/dL; mild/none: ≥10 g/dL), and clinical outcomes, including a primary outcome of 30‐day hospital readmission and secondary outcomes of posthospitalization RBC transfusion, composite stroke or myocardial infarction, and mortality.ResultsA total of 3129 patients were included: 165 (5%) with severe discharge anemia, 1962 (63%) moderate, and 1002 (32%) with mild/none. Five hundred ninety‐two (19%) were readmitted, with the highest rates observed with severe anemia (26% vs 19% for mild/none). Readmissions were not significantly different after multivariable adjustment (overall P = .216); however, in those receiving postoperative intensive care, severe anemia was associated with increased readmission rates (hazard ratio [HR], 1.72; 95% confidence interval [CI], 1.09‐2.71; reference mild/none]. Posthospitalization RBC transfusion rates were highest with severe anemia (25% vs 10% for mild/none; adjusted HR, 2.2; 95% CI, 1.5‐3.3; P < .001). There were no significant differences in composite stroke/myocardial infarction, or mortality. RBC transfusion volumes did not modify anemia‐outcome relationships.ConclusionHospital discharge hemoglobin values for transfused surgical patients were not associated with hospital readmission rates except for those receiving postoperative intensive care. Further evaluation is warranted to understand downstream consequences of postsurgical anemia.
New-Onset Atrial Fibrillation Detected by Continuous Capnography Monitoring: A Case Report
Fiorda‐Diaz, Juan , Ariyoshi, Makiko, Dahan, Albert , Overdyk, Frank J. , Weingarten, Toby N. , Morimatsu, Hiroshi , Bergese, Sergio D. , Šprung, Juraj

Mayo Clinic

American Journal of Case Reports | August 14, 2020 | Volume: 21 | Issue: No issue available | Pages: No page available

10.12659/ajcr.925510 | PMID 32948738 Get It

Development and Validation of Cervical Prediction Models for Patient-Reported Outcomes at 1 Year After Cervical Spine Surgery for Radiculopathy and Myelopathy
Archer, Kristin R. , Bydon, Mohamad , Khan, Inamullah , Nian, Hui , Pennings, Jacquelyn S. , Sivaganesan, Ahilan, Chotai, Silky , McGirt, Matthew J., Foley, Kevin T. , Glassman, Steven D. , Mummaneni, Praveen V. , Bisson, Erica F. , Knightly, John J. , Shaffrey, Christopher I. , Asher, Anthony L. , Devin, Clinton J. , Harrell, Frank E.

Mayo Clinic

Spine | August 13, 2020 | Volume: 45 | Issue: 22 | Pages: 1541-1552

10.1097/brs.0000000000003610 | PMID 32796461 Get It

Study Design. Retrospective analysis of prospectively collected registry data. Objective. To develop and validate prediction models for 12-month patient-reported outcomes of disability, pain, and myelopathy in patients undergoing elective cervical spine surgery. Summary of Background Data. Predictive models have the potential to be utilized preoperatively to set expectations, adjust modifiable characteristics, and provide a patient-centered model of care. Methods. This study was conducted using data from the cervical module of the Quality Outcomes Database. The outcomes of interest were disability (Neck Disability Index:), pain (Numeric Rating Scale), and modified Japanese Orthopaedic Association score for myelopathy. Multivariable proportional odds ordinal regression models were developed for patients with cervical radiculopathy and myelopathy. Patient demographic, clinical, and surgical covariates as well as baseline patient-reported outcomes scores were included in all models. The models were internally validated using bootstrap resampling to estimate the likely performance on a new sample of patients. Results. Four thousand nine hundred eighty-eight patients underwent surgery for radiculopathy and 2641 patients for myelopathy. The most important predictor of poor postoperative outcomes at 12-months was the baseline Neck Disability Index score for patients with radiculopathy and modified Japanese Orthopaedic Association score for patients with myelopathy. In addition, symptom duration, workers’ compensation, age, employment, and ambulatory and smoking status had a statistically significant impact on all outcomes (P < 0.001). Clinical and surgical variables contributed very little to predictive models, with posterior approach being associated with higher odds of having worse 12-month outcome scores in both the radiculopathy and myelopathy cohorts (P < 0.001). The full models overall discriminative performance ranged from 0.654 to 0.725. Conclusions. These predictive models provide individualized risk-adjusted estimates of 12-month disability, pain, and myelopathy outcomes for patients undergoing spine surgery for degenerative cervical disease. Predictive models have the potential to be used as a shared decision-making tool for evidence-based preoperative counselling. Level of Evidence: 2.
Lumbar Puncture Increases Risk of Lumbar Degenerative Disc Disease
Moinuddin, F. M. , Wahood, Waseem , Yolcu, Yagiz U. , Alvi, Mohammed Ali , Frank, Ryan D. , Bydon, Mohamad , Yolcu, Yagiz, Alvi, Mohammed Ali , Goyal, Anshit

Mayo Clinic

Spine | August 12, 2020 | Volume: 45 | Issue: 20 | Pages: E1326-E1332

10.1097/brs.0000000000003595 | PMID 32694488 Get It

Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer
Koehler, Viktoria Florentine , Adam, Pia , Frank‐Raue, Karin, Raue, Friedhelm , Berg, Elke, Hoster, Eva , Allelein, Stephanie, Kroiß, Matthias , Spitzweg, Christine , Glands, on Behalf of the German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid, Kroiss, Matthias , Hoster, Eva , Schott, Matthias , Glands, on Behalf of the German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid

Mayo Clinic

Thyroid® | August 12, 2020 | Volume: 31 | Issue: 3 | Pages: 459-469

10.1089/thy.2020.0206 | PMID 32781914 Get It

Background: Management of patients with advanced medullary thyroid cancer (MTC) remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) vandetanib and cabozantinib have been approved for the treatment of progressive MTC based on prolonged progression-free survival (PFS) in phase 3 clinical trials. Patients and Methods: To evaluate clinical characteristics, treatment regimens, efficacy, and treatment emergent adverse events (TEAEs) of vandetanib and cabozantinib in MTC patients outside clinical trials at four German tertiary care centers. Forty-eight patients diagnosed between 1990 and 2018 were included. PFS and overall survival (OS) probabilities were estimated using the Kaplan–Meier method and compared by log-rank test. Results: The median age at diagnosis was 46 years (15–80 years); a germ line RET (rearranged during transfection) mutation was known in 6 (13%) patients. Thirty-two (67%) patients showed progressive disease before TKI initiation. Forty-seven (98%) patients were treated with vandetanib and 23 (48%) patients with cabozantinib. Vandetanib was first-line treatment in 41 (85%) patients and cabozantinib in 7 (15%) patients. Partial response was the best response in 12 (26%) patients treated with vandetanib and in 5 (22%) patients treated with cabozantinib. Sixteen (34%) patients treated with vandetanib and 3 (13%) patients treated with cabozantinib had stable disease ≥24 weeks. The median PFS for vandetanib and cabozantinib was 17 months [95% confidence interval, CI, 9.3–24.6 months] and 4 months [CI 3.1–4.9 months], respectively. The 6- and 12-month survival rates were 98% and 86% for vandetanib and 78% and 70% for cabozantinib, respectively. The median OS for vandetanib and cabozantinib was 53 months [CI 43.7–62.3 months] and 24 months [CI 5.9–42.1 months], respectively. In vandetanib-treated patients, the PFS and OS were significantly longer in patients aged ≤60 years at TKI initiation and in patients with ≥5 TEAEs. Additionally, the PFS was longer in the absence of bone metastases. In cabozantinib-treated patients, the PFS was significantly longer in patients experiencing TEAEs and in patients aged ≤60 years, and the OS was significantly longer in patients who had TEAEs and in patients with ≥5 TEAEs. Conclusions: Vandetanib and cabozantinib are effective treatment options in the majority of MTC patients. We hypothesize that the poorer prognosis of cabozantinib-treated patients in our retrospective analysis is most likely due to its use as second-line treatment after treatment failure on vandetanib. However, different degrees of efficacy of the two drugs are possible.
Arrhythmia exacerbation after post-infarction ventricular tachycardia ablation: prevalence and prognostic significance
Siontis, Konstantinos C. , Kim, Hyungjin Myra , Vergara, Pasquale , Peretto, Giovanni , H, Duc, Riva, Marta , Lam, Anna, Qian, Pierre , Yokokawa, Miki , Jongnarangsin, Krit, Latchamsetty, Rakesh , Sacher, Fred, Tedrow, Usha B. , Shivkumar, Kalyanam , Zeppenfeld, Katja , Bella, Paolo Della , Stevenson, William G. , Morady, Fred, Bogun, Frank , Zeppenfeld, Katja , Shivkumar, Kalyanam , Zeppenfeld, Katja , Do, Duc H, Jaı̈s, Pierre

Mayo Clinic

EP Europace | August 8, 2020 | Volume: 22 | Issue: 11 | Pages: 1680-1687

10.1093/europace/euaa169 | PMID 32830247 Get It

Abstract Aims Catheter ablation is an effective treatment for post-infarction ventricular tachycardia (VT). However, some patients may experience a worsened arrhythmia phenotype after ablation. We aimed to determine the prevalence and prognostic impact of arrhythmia exacerbation (AE) after post-infarction VT ablation. Methods and results A total of 1187 consecutive patients (93% men, median age 68 years, median ejection fraction 30%) who underwent post-infarction VT ablation at six centres were included. Arrhythmia exacerbation was defined as post-ablation VT storm or incessant VT in patients without prior similar events. During follow-up (median 717 days), 426 (36%) patients experienced VT recurrence. Events qualifying as AE occurred in 67 patients (6%). Median times to VT recurrence with and without AE were 238 [interquartile range (IQR) 35–640] days and 135 (IQR 22–521) days, respectively (P = 0.25). Almost half of the patients (46%) who experienced AE experienced it within 6 months of the index procedure. Patients with AE had had longer ablation times during the ablation procedures compared to the rest of the patients (median 42 vs. 34 min, P = 0.02). Among patients with VT recurrence, the risk of death or heart transplantation was significantly higher in patients with than without AE (hazard ratio 1.99, 95% CI 1.28–3.10; P = 0.002) after adjusting for age, gender, ejection fraction, cardiac resynchronization therapy, post-ablation non-inducibility, and post-ablation amiodarone use. Conclusion Arrhythmia exacerbation after ablation of infarct-related VT is infrequent but is independently associated with an adverse long-term outcome among patients who experience a VT recurrence. The mechanisms and mitigation strategies of AE after catheter ablation require further investigation.